Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Pomegranate For Prostate Cancer
Pomegranate juice may be beneficial in men who have undergone standard treatment for localized prostate cancer, according to a long-term study presented at the 104th Annual Scientific Meeting of the American Urological Association.
generic viagra online
Swine Flu Daily Update Issued At: 11am Thursday 9 July 2009, Wales
-- The NPHS influenza surveillance scheme, which records reports of diagnoses of flu from more than 300 GP practices across Wales, shows low levels of influenza activity in all parts of Wales. Further detail can be found on the NPHS website: http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=38241
News of the day
ImClone Systems And Bristol-Myers Squibb Announce Revisions To ERBITUX(R) (cetuximab) U.S. Product Labeling For Metastatic Colorectal Cancer
ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY), and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved revisions to the U.S. prescribing information for ERBITUX® (cetuximab) concerning the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC). The labeling revisions include a modification to the indication, which now includes a statement that retrospective subset analyses of metastatic or advanced colorectal cancer trials have not shown a treatment benefit for ERBITUX in patients whose tumors had K-ras mutations in codon 12 or 13 and that the use of ERBITUX is not recommended for the treatment of colorectal cancer with these mutations. Revisions concerning the use of ERBITUX in colorectal cancer tumors with K-ras mutations were also made to the clinical studies and clinical pharmacology sections of the product"s prescribing information.
Sexual Health

Terminally Ill Patients And Their Physicians Delay Conversations About End-of-Life Choices, Study Finds

About half of terminally ill patients do not have discussions with their physicians regarding end-of-life choices, according to a Harvard Medical School study published in the Archives of Internal Medicine, the Boston Globe reports.The study, funded by the National Cancer Institute, examined files on 1,517 patients in California, Iowa and Alabama with metastasized lung cancer. According to the Globe, a majority of patients diagnosed with metastasized lung cancer do not survive two years. Researchers asked the patients whether a physician or other health care provider had recommended hospice care or discussed end-of-life care preferences with them. According to the study, about 49% of blacks and 43% of Hispanics had discussed end-of-life care preferences with a physician or health care provider within four to seven months of their diagnosis, compared with 53% of whites and 57% of Asians. Lead study author Haiden Huskamp, an associate professor at Harvard Medical School, said, "Patients who had unrealistic expectations about how long they had to live were much less likely to talk about hospice with their doctor." Huskamp theorized that patients who said they did not discuss end-of-life options with providers might not have completely understood their prognosis or chose to believe in a better outcome. Huskamp also said physicians typically are not well-trained to handle some delicate conversations (Lazar, Boston Globe, 5/26). An abstract of the study is available online. Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009